CoreCap Advisors’s Anixa Biosciences ANIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $182K | Buy |
62,020
+10,000
| +19% | +$32.2K | 0.01% | 879 |
|
|
2026
Q2 | $146K | Hold |
52,020
| – | – | ﹤0.01% | 977 |
|
|
2026
Q1 | $134K | Buy |
52,020
+3,985
| +8% | +$11.8K | ﹤0.01% | 932 |
|
|
2025
Q4 | $150K | Buy |
48,035
+1,248
| +3% | +$5.11K | 0.01% | 887 |
|
|
2025
Q3 | $154K | Hold |
46,787
| – | – | 0.01% | 877 |
|
|
2025
Q2 | $154K | Buy |
46,787
+2,000
| +4% | +$5.71K | 0.01% | 837 |
|
|
2025
Q1 | $128K | Hold |
44,787
| – | – | 0.01% | 817 |
|
|
2024
Q4 | $104K | Hold |
44,787
| – | – | ﹤0.01% | 916 |
|
|
2024
Q3 | $141K | Sell |
44,787
-2,107
| -4% | -$6.48K | 0.01% | 795 |
|
|
2024
Q2 | $104K | Buy |
46,894
+2,600
| +6% | +$7.37K | 0.01% | 489 |
|
|
2024
Q1 | $138K | Buy |
+44,294
| New | +$177K | 0.01% | 735 |
|
|
2022
Q4 | $154K | Sell |
36,209
-1,177
| -3% | -$5.66K | 0.01% | 596 |
|
|
2022
Q3 | $184K | Buy |
37,386
+250
| +0.7% | +$1.01K | 0.02% | 492 |
|
|
2022
Q2 | $114K | Sell |
37,136
-480
| -1% | -$1.51K | 0.01% | 648 |
|
|
2022
Q1 | $103K | Buy |
37,616
+2,664
| +8% | +$7.82K | 0.01% | 535 |
|
|
2021
Q4 | $104K | Buy |
+34,952
| New | +$141K | 0.01% | 730 |
|
CoreCap Advisors's ANIX Position: Q3 2026 in Review
CoreCap Advisors increased its Anixa Biosciences (ANIX) stake by 19% in Q3 2026, buying an estimated $32.2K and bringing the position to 62,020 shares worth $182K. The position accounts for 0.01% of the portfolio, ranked #879.
CoreCap Advisors first reported a position in ANIX in Q4 2021 and has held it in 16 quarters since. The position peaked at $184K in Q3 2022. 1 fund tracked by Wall St. Rank holds ANIX as of Q3 2026.
- CoreCap Advisors held 62,020 shares of Anixa Biosciences worth $182K as of Q3 2026.
- CoreCap Advisors bought 10,000 Anixa Biosciences shares in Q3 2026, an estimated $32.2K.
- Anixa Biosciences made up 0.01% of CoreCap Advisors's portfolio in Q3 2026, its #879 holding.
- CoreCap Advisors first reported a position in Anixa Biosciences in Q4 2021 and has held it in 16 quarters since.
- CoreCap Advisors's Anixa Biosciences position peaked at $184K in Q3 2022.
- 1 fund tracked by Wall St. Rank held Anixa Biosciences as of Q3 2026.
Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.